🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesPost-prandial glucose control — looking for input Page 2

Post-prandial glucose control — looking for input

Dr.Martinez Mon, Jul 22, 2024 at 3:46 PM 35 replies 2,485 viewsPage 2 of 7
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Jul 22, 2024 at 11:42 PM#6
SarahChen_PharmD said:
Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction…

My labs after 6 months on glycaemic control: A1C 6.4%, fasting glucose 84 mg/dL, fasting insulin 9 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 8.3% and fasting glucose was 139 mg/dL. The improvement has been dramatic and consistent.

50 20tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 47 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Jul 23, 2024 at 2:49 AM#7
Dr.Martinez said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 21%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

Last edited: Jul 23, 2024 at 5:49 AM
49 19AmyNC_wife, SkepticalSean, Dr.CardioMD and 46 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Jul 23, 2024 at 5:56 AM#8
BariatricNurseD said:
My labs after 6 months on glycaemic control: A1C 6.4%, fasting glucose 84 mg/dL, fasting insulin 9 uIU/mL.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1131079385
Insulin (fasting)191595
HOMA-IR5.53.42.11.2
Uric Acid8.16.36.04.9

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.

48 18TomTeleRx, DoseLogDan, SleepFixSam and 45 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
DerekSJ_a1c
Member
378
1,678
Aug 2024
San Jose, CA
Jul 23, 2024 at 9:03 AM#9

Following on from labquiet_amy — and this may be the naive question:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Jul 23, 2024 at 2:03 PM
47 17traveltech_sara, AttorneyGrant, DebRD_ATL and 44 others
Reply Quote Save Share Report
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Jul 24, 2024 at 12:00 AM#10
TrialNerd_Beth said:
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 10 months: periods became regular for the first time in years, testosterone levels normalized, acne cleared significantly, and — unexpectedly — I got pregnant naturally after 4 years of trying.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

Last edited: Jul 24, 2024 at 5:00 AM
31 6adam_van, Dr.SurgeonPGH, rachel_ABQ and 28 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register